Skip to search formSkip to main contentSkip to account menu

Vastarel

Known as: Biopharma Brand of Trimetazidine Dihydrochloride 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Trimetazidine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B
Introduction: Recombinant factor IX Fc fusion protein (rFIXFc) is an extended half-life therapy for severe hemophilia B. The… 
2018
2018
DNA Methyltransferase Inhibitors Increase Expression of CD38 and Enhance Daratumumab Efficacy in Multiple Myeloma
Introduction: The anti-CD38 monoclonal antibody Daratumumab is highly effective against multiple myeloma, is well tolerated… 
2017
2017
PRN1008, a Reversible Covalent BTK Inhibitor in Clinical Development for Immune Thrombocytopenic Purpura
PRN1008 is an oral, reversible covalent inhibitor of Bruton9s tyrosine kinase (BTK) in clinical development for the treatment of… 
Review
2017
Review
2017
Sensory Neuropathic Symptoms in Postural Tachycardia Syndrome: Insights from a Cross-Sectional Community-Based Survey (P5.322)
Objective: Identification of patient-reported sensory symptoms in postural tachycardia syndrome (POTS). Background: POTS is a… 
2015
2015
THU0068 Preclinical Characterization of PRN1008, a Novel Reversible Covalent Inhibitor of BTK that Shows Efficacy in a RAT Model of Collagen-Induced Arthritis
Background Bruton's Tyrosine Kinase (BTK) is a cytoplasmic signaling molecule downstream from a group of cellular receptors… 
2015
2015
Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation
Janus kinase 2 (JAK2) signal transduction is a critical mediator of immune response. JAK2 activation promotes T-cell… 
2014
2014
Re-inventing clinical trials through TransCelerate
TransCelerate BioPharma was formed in 2012 as a non-profit organization with a mission to collaborate across the… 
2013
2013
Money without collaboration won't bring cures
It's up to stakeholders at every stage of therapeutic development—industry and academic researchers, policymakers, patient… 
2013
2013
Principia Biopharma
A University of California, San Francisco, startup offers a reversible twist on covalent drugs. 
2007
2007
A Standard Computable Clinical Trial Protocol: The Role of the BRIDG Model
Today’s clinical trial processes are inefficiently mired in excessive documentation and unnecessary human intervention. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)